Pantoprazole (Pantoprazole Sodium Sesquihydrate)

Adult dosage

If oral administration of pantoprazole is not appropriate, dissolve 10 mL of normal saline injection in each vial of this medicine (equivalent to 40 mg of pantoprazole) and administer by direct intravenous injection, or mix this solution with 100 mL of normal saline injection or 5 % dextrose solution and administer intravenously over 2∼15 minutes. As soon as oral administration becomes possible, discontinue intravenous pantoprazole and switch to oral pantoprazole 40 mg. 1. Duodenal ulcer, gastric ulcer, moderate to severe reflux esophagitis Administer 1 vial of this medicine (equivalent to 40 mg of pantoprazole) intravenously once daily. 2. Zollinger-Ellison syndrome and other pathological hypersecretory conditions - Start with an initial dose of 80 mg per day, then increase or decrease the dose according to measurements of gastric acid secretion. - Doses of 80 mg or more should be administered in 2 divided doses per day. - A temporary increase to 160 mg or more is possible, but should be used only for as long as necessary to achieve adequate acid control. - When rapid acid control is required, an initial dose of 2 × 80 mg reduced acid output to the target range (< 10 mEq/h) within one hour in most patients. ◯ In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. ◯ In elderly patients or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This medication should not be used in patients with hypersensitivity to certain ingredients or those who have experienced allergic reactions such as anaphylaxis, angioedema, or bronchospasm in the past. Furthermore, patients currently on certain antiviral drugs or those being treated with antiviral agents should not receive this medication. Caution is required when using this medication, as various side effects may occur. Relatively common symptoms include dyspepsia, diarrhea, headache, dizziness, and skin rash; however, rare but serious adverse reactions have also been reported, including severe liver damage, severe allergic reactions, skin diseases, and kidney problems. Regular check-ups are needed for long-term use, especially to monitor liver function. This drug is not suitable for mild dyspepsia and may require additional testing if symptoms persist. Patients with severely impaired liver function should reduce the dose, and treatment should be discontinued if liver enzyme levels increase. Long-term use may increase the risk of fractures, so caution is necessary. Additionally, long-term use may lead to hypomagnesemia, so blood magnesium levels should be monitored periodically. This medication suppresses gastric acid secretion, which may increase the risk of bacterial infections in the gastrointestinal tract, so consult with healthcare professionals if diarrhea persists. Dizziness or visual disturbances may occur, so caution is advised when driving or operating machinery. This drug may interact with various medications, so inform your doctor if you are taking other medications. Caution is especially needed when used in conjunction with anticoagulants, methotrexate, or certain antivirals. It is advisable not to use this medication during the first three months of pregnancy, and it should only be used during pregnancy if the potential benefits outweigh the risks. It is recommended that breastfeeding women do not use this medication. There is insufficient experience to recommend use in children or adolescents under 18 years of age. Although no special safety differences exist for the elderly, caution is warranted based on their condition. No specific symptoms have been reported in cases of overdose, but if unusual symptoms occur, consult healthcare professionals immediately. This drug should be prepared and stored according to instructions before administration, and do not use if the product is discolored or contaminated. Long-term use may increase the risk of gastric polyps, so the minimum effective dose and shortest duration of use are recommended. If any abnormal reactions occur in the skin or body during the course of taking this medication, notify healthcare professionals immediately for evaluation.

• Anaphylaxis
• anaphylactic shock
• angioedema
• bronchospasm
• acute interstitial nephritis
• urticaria
• agranulocytosis
• leukopenia
• thrombocytopenia
• pancytopenia

This drug may be sensitive to light, so it should be stored in a tightly closed container that does not allow light to enter. Additionally, it is important to store it at a cool temperature below 25 degrees Celsius to maintain the drug's effectiveness.

Appearance

This drug is a colorless, transparent vial containing a white to almost white dry powder.

Package unit

46.1 mg/vial [1 vial (46.1 mg/vial)]